Immunological memory to herpes simplex virus type 1 glycoproteins B and D in mice

Abstract

Mouse L cell lines constitutively expressing glycoproteins B or D of herpes simplex virus type 1 (LTKgB and LTKgD respectively) were used to study the longevity of the immune response to these viral glycoproteins in mice. Two immunizations with the cell lines were necessary to induce a persisting antibody response (present for over 200 days). Only LTKgD induced a neutralizing antibody response in mice and this also remained at high titres over 200 days after two inoculations. The presence in mice of precursor cytotoxic T lymphocytes specific for gB expressed in the L cells was also shown up to 270 days after immunization. Mice immunized with the cell lines showed an increased rate of virus clearance from the ear pinna, inoculation with LTKgD resulting in more clearance than LTKgB at 7 days post-immunization, This type of protection was reduced with time after inoculation, until by day 161 there was no significant difference in virus titres between immunized and control groups. However, LTKgD immunization protected against the establishment of latent infections in the ganglia of mice even up to 186 days postinoculation.

Characterization of immune responses to baculovirus-expressed equine herpesvirus type 1 glycoproteins D and H in a murine model

“…However our results are similar to earlier findings that no neutralizing antibody response was induced by vaccinia virus-expressed gH, a result which was attributed to differing behaviour of gH during expression in mammalian cells, in the absence of an accompanying gL molecule (Blacklaws & Nash, 1990;Hutchinson et al, 1992). In our experiments, the recognition of a l15K form of EHV-1 gH from insect cells by both equine and murine sera suggests that the processing of the gH molecule is similar to that occurring in normal EHV-1 infection.…”

“…Protection against lethal infections in animals has been demonstrated for a range of recombinant glycoproteins of HSV-1 including gB, gC, gD and gI (Blacklaws & Nash, 1990;Ghiasi et al, 1991aGhiasi et al, , b, 1992a. In comparison with HSV, relatively little is known about immune responses to the glycoproteins of equine herpesvirus type 1 (EHV-1), an agent that causes respiratory illness, abortion and neurological symptoms in the horse.…”

Anti-glycoprotein B monoclonal antibody protects T cell-depleted mice against herpes simplex virus infection by inhibition of virus replication at the inoculated mucous membranes

“…However, they are not equally engaged in the different target tissues of infection. Antibodies are important in restricting ganglionic infection, thus inhibiting the spread of virus to the central nervous system, whereas cell-mediated immunity is important in clearing the virus from the primary infection site (Kapoor et al, 1982a, b;Nash et al, 1987;Simmons & Nash, 1987;Blacklaws & Nash, 1990). Recently, we described a MAb against HSV-1 gB (MAb 2c), which mediates clearance of infectious virus from the mucous membranes of immunocompetent mice following antibody transfer on days 1 and 3 after viral inoculation.…”

N-terminal sequence analysis of equine herpesvirus 1 glycoproteins D and B and evidence for internal cleavage of the gene 71 product

“…Envelope glycoproteins of herpesviruses play essential roles in the infectious process, viral pathogenesis and interaction with the host immune system (Spear, 1985;Blacklaws & Nash, 1990;Manservigi & Cassai, 1991). The primary translation products of many herpesvirus glycoproteins, like other viral glycoproteins, share features characteristic of class 1 membrane proteins (Wiley, 1985).…”